Rebooted Merrimack names Sanofi Genzyme SVP as CEO

Employment contract
Peters will take responsibility for making a success of Merrimack's reboot strategy

Merrimack Pharmaceuticals has lured Dr. Richard Peters from Sanofi Genzyme to serve as its CEO. Peters will take charge of a rebooted, slimmed-down organization that is focused on pushing three anticancer candidates through clinical proof of concept.

The appointment ends the search for a CEO that began when Robert Mulroy resigned in October. Since then, Gary Crocker has helmed the company, during which time it struck a deal with Ipsen to offload FDA-approved cancer drug Onivyde. That deal led Merrimack to further cut its staffing levels, resulting in the company Peters takes charge of looking very different from that left behind by Mulroy three months ago.

Responsibility for making a success of the plan will fall on Peters, a physician-scientist who spent the past nine years at Sanofi Genzyme. Peters joined Sanofi Genzyme as a medical affairs VP after spells at Onyx Pharmaceuticals and Amgen, and went on to rise to the post of head of global rare diseases.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

That position gave Peters control of a $3 billion-a-year business with 10 commercial products. The new Merrimack, which is about to sell its one approved product, poses a different challenge.

Once the deal with Ipsen goes through, Merrimack will have $575 million more in cash, far fewer employees and no revenue generating products. That puts the focus on getting three experimental candidates to clinical proof of concept.

"With the support of the board of directors and the expected near-term infusion of capital, several compelling clinical assets are now primed to realize their full potential. Together with the rest of the management team, we plan on continuing to take substantial steps to grow our robust pipeline to its full potential, with an eye toward early data readouts,” Peters said in a statement.

The cash infusion from Ipsen is expected to see Merrimack through to the middle of 2019, by when the merits of the company’s decision to tie its fate to MM-121, MM-141 and MM-310 should be clearer.

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.